Table 2.
Highlighted Metabolites significantly increased with an Increase in 25(OH)D
| Metabolite | P-value | Bonferroni corrected P-value | −log10p | β Coefficient | Super Pathway | Sub Pathway |
|---|---|---|---|---|---|---|
| 1-lignoceroyl-GPC (24:0) | 3.27 E-07 | 1.89 E-04 | 6.49 | 0.0047 | Lipid | Lysophospholipid |
| 1-cerotoyl-GPC (26:0)* | 2.11 E-06 | 1.22 E-03 | 5.67 | 0.0038 | Lipid | Lysophospholipid |
| 2-palmitoyl-GPC (16:0)* | 5.49 E-05 | 3.17 E-02 | 4.26 | 0.0031 | Lipid | Lysophospholipid |
| 1-arachidonoyl-GPC (20:4)* | 5.37 E-05 | 3.10 E-02 | 4.27 | 0.0030 | Lipid | Lysophospholipid |
| 1-(1-enyl-palmitoyl)-GPC (P-16:0)* | 1.08 E-10 | 6.26 E-08 | 9.97 | 0.0054 | Lipid | Lysoplasmalogen |
| 1-(1-enyl-stearoyl)-GPE (P-18:0)* | 1.57 E-08 | 9.06 E-06 | 7.80 | 0.0047 | Lipid | Lysoplasmalogen |
| 1-(1-enyl-oleoyl)-GPE (P-18:1)* | 4.32 E-06 | 2.50 E-03 | 5.36 | 0.0041 | Lipid | Lysoplasmalogen |
| 1-(1-enyl-palmitoyl)-GPE (P-16:0)* | 2.86 E-06 | 1.65 E-03 | 5.54 | 0.0039 | Lipid | Lysoplasmalogen |
| 1-(1-enyl-palmitoyl)-2-linoleoyl-GPE (P-16:0/18:2)* | 4.02 E-14 | 2.32 E-11 | 13.40 | 0.0063 | Lipid | Plasmalogen |
| 1-(1-enyl-stearoyl)-2-arachidonoyl-GPE (P-18:0/20:4)* | 5.79 E-15 | 3.35 E-12 | 14.24 | 0.0061 | Lipid | Plasmalogen |
| 1-(1-enyl-stearoyl)-2-linoleoyl-GPE (P-18:0/18:2)* | 8.42 E-14 | 4.87 E-11 | 13.07 | 0.0053 | Lipid | Plasmalogen |
| 1-(1-enyl-palmitoyl)-2-linoleoyl-GPC (P-16:0/18:2)* | 8.62 E-11 | 4.98 E-08 | 10.06 | 0.0046 | Lipid | Plasmalogen |
| Sphingomyelin (d18:1/21:0, d17:1/22:0, d16:1/23:0)* | 2.01 E-08 | 1.16 E-05 | 7.70 | 0.0044 | Lipid | Sphingomyelins |
| Tricosanoyl sphingomyelin (d18:1/23:0)* | 2.79 E-09 | 1.61 E-06 | 8.55 | 0.0043 | Lipid | Sphingomyelins |
| Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1)* | 7.85 E-08 | 4.54 E-05 | 7.11 | 0.0039 | Lipid | Sphingomyelins |
| Lignoceroyl sphingomyelin (d18:1/24:0) | 2.15 E-08 | 1.24 E-05 | 7.67 | 0.0038 | Lipid | Sphingomyelins |
| Sphingomyelin (d18:1/19:0, d19:1/18:0)* | 4.61 E-07 | 2.66 E-04 | 6.34 | 0.0037 | Lipid | Sphingomyelins |
| Sphingomyelin (d17:1/14:0, d16:1/15:0)* | 3.14 E-05 | 1.82 E-02 | 4.50 | 0.0034 | Lipid | Sphingomyelins |
| Sphingomyelin (d18:1/25:0, d19:0/24:1, d20:1/23:0, d19:1/24:0)* | 4.65 E-05 | 2.69 E-02 | 4.33 | 0.0031 | Lipid | Sphingomyelins |
| Sphingomyelin (d17:2/16:0, d18:2/15:0)* | 5.97 E-05 | 3.45 E-02 | 4.22 | 0.0031 | Lipid | Sphingomyelins |
| Sphingomyelin (d18:2/21:0, d16:2/23:0)* | 4.15 E-05 | 2.40 E-02 | 4.38 | 0.0030 | Lipid | Sphingomyelins |
Note: Increase in 25(OH)D is defined as the absolute ng/ml increase in plasma 25(OH)D from baseline day 0 to day 3 following randomization.
*
indicates the metabolite has a recognized identification with predictive or externally acquired structure evidence. All other Metabolites have validated identification against a pure reference standard. GPC is glycerylphosphorylcholine; GPE is glycerophosphoethanolamine. All significant mixed-effects associations have P-value < 8.65 × 10−5.